Podcast
Questions and Answers
What was the primary outcome of the meta-analysis described in the text?
What was the primary outcome of the meta-analysis described in the text?
- All fractures, (major) osteoporotic fractures, and hip fractures (correct)
- Hip fractures only
- Skull and foot fractures
- Osteoporotic fractures and all-cause mortality
What criteria were used to define major osteoporotic fractures?
What criteria were used to define major osteoporotic fractures?
- All upper and lower extremity fractures
- Fractures of the spine and hips
- All fractures except skull, finger, hand, toe, and foot fractures
- All hip, vertebral, wrist, and humerus fractures (correct)
How was between-study heterogeneity estimated?
How was between-study heterogeneity estimated?
- Using I2-statistics (correct)
- Using chi-square statistics
- Using t-tests
- Using p-values
What was the principal summary measure used in the meta-analysis?
What was the principal summary measure used in the meta-analysis?
What was excluded in the post-hoc sensitivity analysis?
What was excluded in the post-hoc sensitivity analysis?
How many articles reported trials on screening for fracture prevention?
How many articles reported trials on screening for fracture prevention?
Which studies were included in the meta-analysis?
Which studies were included in the meta-analysis?
What is the ultimate goal of osteoporosis care?
What is the ultimate goal of osteoporosis care?
What is the treatment gap referred to in the text?
What is the treatment gap referred to in the text?
Why has screening for high fracture risk not been implemented in the UK and the Netherlands?
Why has screening for high fracture risk not been implemented in the UK and the Netherlands?
Which country recommends bone mineral density measurements for all men and women aged 65 and older?
Which country recommends bone mineral density measurements for all men and women aged 65 and older?
What was observed in one study regarding hip fractures and the screening group compared with usual care?
What was observed in one study regarding hip fractures and the screening group compared with usual care?
What is the current challenge in osteoporosis care according to the text?
What is the current challenge in osteoporosis care according to the text?
What has been observed in several large randomized screening studies for fracture prevention?
What has been observed in several large randomized screening studies for fracture prevention?
What did different countries have varied policies on with respect to population screening for high fracture risk?
What did different countries have varied policies on with respect to population screening for high fracture risk?
What was the reason for performing a sensitivity analysis on hip fractures without the findings from the SCOOP study?
What was the reason for performing a sensitivity analysis on hip fractures without the findings from the SCOOP study?
Why did the participation rate vary in the screening programs of the three studies?
Why did the participation rate vary in the screening programs of the three studies?
What was a limitation of the study according to the text?
What was a limitation of the study according to the text?
Why did the authors pool results from participants with baseline FRAX data in one of the studies?
Why did the authors pool results from participants with baseline FRAX data in one of the studies?
What was observed in a recent trial examining the effect of 5-mg zoledronate infusions at 18-month intervals?
What was observed in a recent trial examining the effect of 5-mg zoledronate infusions at 18-month intervals?
Why is it stated that a fracture-reducing intervention is unlikely to be cost-effective if it does not lead to a reduction of hip fractures?
Why is it stated that a fracture-reducing intervention is unlikely to be cost-effective if it does not lead to a reduction of hip fractures?
What does the text suggest about the need for BMD and fracture risk assessment before initiating anti-osteoporosis medication?
What does the text suggest about the need for BMD and fracture risk assessment before initiating anti-osteoporosis medication?
What does the text recommend policymakers and guideline committees consider based on the current findings?
What does the text recommend policymakers and guideline committees consider based on the current findings?
What was the number needed to treat for an osteoporotic fracture among the women in the group with an increased fracture risk who started anti-osteoporosis medication?
What was the number needed to treat for an osteoporotic fracture among the women in the group with an increased fracture risk who started anti-osteoporosis medication?
What was the number needed to treat for a hip fracture among the women in the group with an increased fracture risk who started anti-osteoporosis medication?
What was the number needed to treat for a hip fracture among the women in the group with an increased fracture risk who started anti-osteoporosis medication?
What was the pooled hazard ratio (HR) for the secondary outcome of all-cause mortality?
What was the pooled hazard ratio (HR) for the secondary outcome of all-cause mortality?
What was the relative risk reduction for major osteoporotic fractures according to the text?
What was the relative risk reduction for major osteoporotic fractures according to the text?
What percentage of participants in the intervention groups were advised to use anti-osteoporosis medication, according to the text?
What percentage of participants in the intervention groups were advised to use anti-osteoporosis medication, according to the text?
How many patients would need to be treated with alendronate for 5 years to prevent one fracture, as per the text?
How many patients would need to be treated with alendronate for 5 years to prevent one fracture, as per the text?
What is the number needed to screen by breast cancer screening, according to the text?
What is the number needed to screen by breast cancer screening, according to the text?
What was the distinct significant relative risk reduction of hip fractures observed in the SCOOP study?
What was the distinct significant relative risk reduction of hip fractures observed in the SCOOP study?
What was the percentage of participants in the intervention group that started medication after screening in the SCOOP study?
What was the percentage of participants in the intervention group that started medication after screening in the SCOOP study?
What was the mean 10-year hip fracture probability in the screened, high-risk group in the SOS study?
What was the mean 10-year hip fracture probability in the screened, high-risk group in the SOS study?
What was the main indication for DXA in the ROSE study?
What was the main indication for DXA in the ROSE study?
What did the pooled hazard ratio (HR) indicate for hip fractures?
What did the pooled hazard ratio (HR) indicate for hip fractures?
In which study was there no blinding of outcome data?
In which study was there no blinding of outcome data?
What was the number needed to screen, starting with the completion of a complete questionnaire, to prevent one hip fracture?
What was the number needed to screen, starting with the completion of a complete questionnaire, to prevent one hip fracture?
What was the percentage of women who underwent bone densitometry examinations to prevent one osteoporotic fracture?
What was the percentage of women who underwent bone densitometry examinations to prevent one osteoporotic fracture?
What was the population age range in the SCOOP study?
What was the population age range in the SCOOP study?
